BioWorld

Sep. 12, 2007

View Archived Issues

Sepracor, GSK Enter $155M Deal Covering Global Lunesta Rights

Sepracor Inc. entered a potential $155 million deal with GlaxoSmithKline plc covering its insomnia product Lunesta in Europe and elsewhere, about six weeks after it filed for European approval of the drug. (BioWorld Today) Read More

ImClone Gains On Erbitux Results; Avastin In Danger?

Read More

Enobia Gets $38M In Series B For Enzyme Replacement Trials

Read More

Nabi's 'Turnaround' Continues, Sells Biologics Unit For $185M

Read More

Aptuit Paying $64M For Evotec Chemistry Unit

Read More

Clinic Roundup

Read More

Other News To Note

Read More